何慶瑜

何慶瑜

何慶瑜博士，“長江學者”特聘教授，國家重點研發計畫項目首席科學家。1995年獲英國謝菲爾德大學（University of Sheffield）生物化學博士學位；曾任英國牛津大學（University of Oxford）訪問學者，美國佛蒙特大學（University of Vermont）博士後及香港大學助理教授(研究)；2006年回國內後被國家人事部、科技部等七部委評為“新世紀百千萬人才工程”國家級人選；2008年入選“長江學者”特聘教授；2010年獲國務院政府特殊津貼；2011年獲得廣東省“五一勞動獎章”。

現任暨南大學生命科學技術學院院長及生命與健康工程研究院院長，教授，博士生導師；兼任中山大學基礎醫學國家級實驗教學示範中心教學指導委員會主任委員（2017- ），暨南大學基因工程藥物國家工程研究中心副主任。是美國ASBMB會員，英國皇家化學會會士(Fellow, FRSC)，中國蛋白質組學專業委員會副理事長和蛋白質專業委員會委員。

基本介紹

  • 中文名：何慶瑜
  • 國籍：中國
  • 職業：教師
  • 畢業院校：University of Sheffield,UK
  • 學位/學歷：博士
  • 職務：暨南大學生命科學技術學院院長及生命與健康工程研究院院長
  • 主要成就：廣東省“五一勞動獎章等
  • 職稱：教授
人物經歷,學習經歷,工作經歷,研究方向,學術成果,主要論文,承擔課題,榮譽獎勵,

人物經歷

學習經歷

1995: PhD, University of Sheffield, UK
1988: MSc, JinanUniversity/Sun Yat-Sen University, China
1985: BSc, Jinan University, China

工作經歷

2005 – Present: Professor and Director, Jinan University, China
2002 – 2006: Assistant Professor (Research), University of Hong Kong, Hong Kong
1996 – 2002: Post Doc. - Research Associate - Research Assistant Professor, University of Vermont, USA
1991 – 1992:Visiting Scholar, University of Oxford, UK

研究方向

  • Disease Proteomics: Biomarker discovery and validation.
  • Drug Proteomics: Drug action mechanism and target discovery.

學術成果

主要論文

Publications (216 in total, google cited:9727 times SCI cited :6845times)
  1. Yang J, Li B,He QY. “Significance of prohibitin domain family in tumorigenesis and its implication in cancer diagnosis and treatment.”Cell Death Dis. doi: 10.1038/s41419-018-0661-3. (IF = 5.965)
  2. Liu WT, Wang Y, Zhang J, Ye F, Huang XH, Li B,He QY. “A novel strategy of integrated microarray analysis identifies CENPA, CDK1 and CDC20 as a cluster of diagnostic biomarkers in lung adenocarcinoma.”Cancer Lett. doi:10.1016/j.canlet.2018.03.043. (IF = 6.375)
  3. Xu WW, Li B, Zhao JF, Yang JG, Li JQ, Tsao SW,He QY, Cheung ALM. “IGF2 induces CD133 expression in esophageal cancer cells to promote cancer stemness.”Cancer Lett.doi: 10.1016/j.canlet.2018.03.039. (IF = 6.375)
  4. Zhang J, Wang Y, Zhou Y,He QY. “Jolkinolide B induces apoptosis of colorectal carcinoma through ROS-ER stress-Ca2+-mitochondria dependent pathway.”Oncotarget. doi: 10.18632/oncotarget.20077. (IF = 5.168)
  5. Zhong Y, Yang J, Xu WW, Wang Y, Zheng CC, Li B,He QY. “KCTD12 promotes tumorigenesis by facilitating CDC25B/CDK1/Aurora A-dependent G2/M transition.”Oncogene. doi: 10.1038/onc.2017.287. (IF = 7.519)
  6. Zhang J, Lu SH, Zhou Y, Meng K, Chen ZP, Cui YZ, Shi YF, Wang T,He QY. “Motile hepatocellular carcinoma cells preferentially secret sugar metabolism regulatory proteins via exosomes.”Proteomics. doi: 10.1002/pmic.201700103. (IF = 4.041)
  7. Wang Y, Zhang J, Huang ZH, Huang XH, Zheng WB, Yin XF, Li YL, Li B,He QY. “Isodeoxyelephantopin induces protective autophagy in lung cancer cells via Nrf2-p62-keap1 feedback loop.”Cell Death Dis. doi: 10.1038/cddis.2017.265. (IF = 5.965)
  8. Li B, Xu WW, Lam AKY, Wang Y, Hu HF, Guan XY, Qin YR, Saremi N, Tsao SW,He QY, Cheung ALM. “Significance of PI3K/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapy.”Oncotarget. doi: 10.18632/oncotarget.16333. (IF = 5.168)
  9. Li B, Xu WW, Han L, Chan KT, Tsao SW, Lee NP, Law S, Xu LY, Li EM, Chan KW, Qin YR, Guan XY,He QY, Cheung AL. “MicroRNA-377 suppresses initiation and progression of esophageal cancer by inhibiting CD133 and VEGF.”Oncogene. doi: 10.1038/onc.2017.29. ( IF = 7.519)
  10. Xu WW, Li B, Guan XY, Chung SK, Wang Y, Yip YL, Law SY, Chan KT, Lee NP, Chan KW, Xu LY, Li EM, Tsao SW,He QY, Cheung AL. “Cancer cell-secreted IGF2 instigates fibroblasts and bone marrow-derived vascular progenitor cells to promote cancer progression.”Nat Commun. doi: 10.1038/ncomms14399. (IF = 12.124)
  11. Gao XJ, Feng JX, He YJ, Xu FM, Fan XQ, Huang WS, Xiong HT, Liu QY, Liu WT, Liu XH, Sun XS,He QY, Zhang QH, Liu LX. “hnRNPK inhibits GSK3beta Ser9 phosphorylation, thereby stabilizing c-FLIP and contributes to TRAIL resistance in H1299 lung adenocarcinoma cells.”Sci Rep. doi: 10.1038/srep22999. (IF = 4.259)
  12. Li B, Xu WW, Guan XY, Qin YR, Law S, Lee NP, Chan KT, Tam PY, Li YY, Chan KW, Yuen HF, Tsao SW,He QY, Cheung AL. “Competitive Binding Between Id1 and E2F1 to Cdc20 Regulates E2F1 Degradation and Thymidylate Synthase Expression to Promote Esophageal Cancer Chemoresistance.”Clin Cancer Res. doi: 10.1158/1078-0432.CCR-15-1196. (IF = 9.619)
  13. Lian XL, Guo JH, Gu W, Cui YZ, Zhong JY, Jin JJ,He QY, Wang T, Zhang G. “Genome-Wide and Experimental Resolution of Relative TranslationlGene Level in Human Cells.”PLoS Genet.doi: 10.1371/journal.pgen.1005901. (IF = 6.1)
  14. Yang XY, He K, Du GF, Wu XH, Yu GC, Pan YL, Zhang G, Sun XS,He QY. “Integrated Translatomics with Proteomics to Identify Novel Iron-Transporting Proteins inStreptococcus pneumoniae.”Front Microbiol. doi: 10.3389/fmicb.2016.00078. (IF = 4.076)
  15. Chen ZP, Yang LJ, Cui YZ, Zhou YL, Yin XF, Guo JH, Zhang G, Wang T,He QY. “Cytoskeleton-centric protein transportation by exosomes transforms tumor-favorable macrophages.”Oncotarget. doi: 10.18632/oncotarget.11794. (IF = 5.168)
  16. Zhong J, Xiao C, Gu W, Du G, Sun X,He QY, Zhang G. “Transfer RNAs Mediate the Rapid Adaptation ofEscherichia colito Oxidative Stress.”PLoS Genet. doi: 10.1371/journal.pgen.1005302. (IF = 6.1)
  17. Yu G, Wang LG,He QY. “ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization.”Bioinformatics. doi: 10.1093/bioinformatics/btv145. (IF = 7.307)
  18. Yu G, Wang LG, Yan GR,He QY. “DOSE: an R/Bioconductor package for disease ontology semantic and enrichment analysis.”Bioinformatics. doi: 10.1093/bioinformatics/btu684. (IF = 7.307)
  19. Li B, Tsao SW, Chan KW, Ludwig DL, Novosyadlyy R, Li YY,He QY, Cheung AL. “Id1-Induced IGF-II and Its Autocrine/Endocrine Promotion of Esophageal Cancer Progression and Chemoresistance-Implications for IGF-II and IGF-IR-Targeted Therapy.”Clin Cancer Res. doi:10.1158/1078-0432.CCR-13-2735. (IF = 9.619)
  20. Wang T, Cui Y, Jin J, Guo J, Wang G, Yin X,He QY, Zhang G. “Translating mRNAs strongly correlate to proteins in a multivariate manner and their translation ratios are phenotype specific.”Nucleic Acids Res. 2013 May;41(9):4743-54. doi: 10.1093/nar/gkt178. (IF = 10.162)

承擔課題

  1. 蛋白質修飾組的高維度鑑定及其功能網路，國家重點研發計畫重點專項項目（2017YFA0505100），3124萬元，2017/7-2022/6，主持。
  2. 細胞周期調節因子KCTD12的發現及其調控機制，國家自然科學基金面上項目（31770888），60萬元，2018/1-2021/12，主持。
  3. 人類新蛋白UBAP1-AST6的發現及其功能研究，國家自然科學基金面上項目（31570828），62萬元，2016/1-2019/12/1，主持。
  4. 功能蛋白質研究與抗癌藥物靶標發現，廣東省自然科學基金團隊項目（S2013030013315），200萬元，2013/10/1-2018/10/1，主持。

榮譽獎勵

長江學者

相關詞條

熱門詞條

聯絡我們